A Study on Technology Transfer and Access to Patented Biological Drugs with Special Reference to The Trips Agreement
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
COVID-19 has rekindled the controversy of patents being an incentive or
newlinedeterrent to access to medicine. It was realised that despite having proper medication,
newlineand pharmaceuticals especially vaccines for the prevention and cure of an ailment
newlinedisease, there was a vast disparity between the nations in access to those drugs, which
newlineled to the recurrence of pandemics. However, the case is not limited to COVID-19
newlinealone, and many patented drugs, especially biological drugs, which play an essential
newlinerole in curing diseases like cancer, arthritis, diabetes, HIV/ AIDS etc., are not
newlineaffordable and accessible to the general public of third-world countries. Patent law
newlineprovides a monopoly to the patent holder in terms of production and supply of the
newlinedrugs. However, it also provides an inbuilt mechanism called technology transfer
newlinewhich helps to maintain a balance between public interest in the form of health rights
newlineand private rights of the patent holder i.e. patent rights. The TRIPS Agreement in its
newlineobjectives and principles clearly mentions that the provisions of the Agreement can be
newlineinterpreted by the member nations in accordance with their socio-economic structure,
newlineand to disseminate technology transfer. During the DOHA Declaration on Public
newlineHealth, the importance of technology and use of TRIPS Agreements flexibilities for
newlineproviding access to pharmaceutical drugs was once again discussed. However, despite
newlinethese flexibilities at the international framework, there is a lack of technology transfer
newlinetaking place is reality.
newlineThe research aims to analyse the extent of technology transfer for patented
newlinebiological drugs in India. It also analyses how the TRIPS Agreement and domestic
newlinepatent laws in countries like the United States, Brazil, South Africa and the European
newlineUnion promote or hinder access to patented biological drugs. By examining the policy
newlineframeworks, and the data available related to technology transfer in the WTO and by
newlineexamining the extent of technology transfer of biological drugs in India, the study aims
newlineto evaluate